India Earnings Roundup: Dr Reddy’s Eyes Biosimilars; Boosts Spending On R&D
This article was originally published in PharmAsia News
Executive Summary
India’s Dr. Reddy’s shrugs off disappointing earnings in the first quarter of its financial year and talks the long-term with plans for greater R&D spending and a more diversified portfolio that includes biosimilars.